Chai Discovery Expands AI Drug Discovery Partnership With Novartis

Chai Discovery has announced a collaboration with Novartis to advance the discovery of therapeutic antibodies using artificial intelligence, expanding an existing technical relationship between the two companies.

Under the agreement, Novartis will gain access to Chai Discovery's latest AI models, including the Chai-3 model, to support antibody discovery across multiple therapeutic programs. The collaboration builds on more than a year of technical engagement, during which Novartis received early access to Chai's next-generation protein folding model last spring.

Joshua Meier, Co-founder and CEO of Chai Discovery, said the collaboration broadens the application of the company's AI-driven molecular design platform across therapeutic programs.

"We are delighted to be collaborating with Novartis in the discovery of new antibodies," Meier said. "This is a significant step forward in expanding the range of therapeutic programs that can benefit from AI-driven molecular design."